print_label | resize_label

Start Onglyza to stand strong against HbA1c

Click here to view the Onglyza SmPC

Start Komboglyze to stand strong against HbA1c

Click here to view the Komboglyze SmPC

Explore saxagliptin’s key clinical data and test your knowledge

View interactive clinical summary

Experience in NYHA class III–IV is still limited. Therefore, caution is warranted in these patients. In the SAVOR trial, a small increase in the rate for hospitalisation for heart failure, occurred at a greater rate in Onglyza-treated patients (3.5%) compared to placebo (2.8%; p=0.007). There was no imbalance in CV deaths due to heart failure (0.5% in each group according to 2-year Kaplan-Meier estimates). Additional analysis did not indicate a differential effect among NYHA classes.1

Komboglyze should not be used in patients with acute or chronic disease which may cause hypoxia, such as cardiac or respiratory failure, recent myocardial infarction or shock.8

The right product for the right patient

Use our patient profiler to understand the differences between our products.

View patient profiler


About Onglyza

Onglyza (saxagliptin) is a DPP-4 inhibitor that is approved for use as monotherapy


Onglyza offers comparable efficacy to a SU as add-on to metformin, with less hypoglycaemia and no weight gain


SAVOR: Onglyza's CV safety profile demonstrated in a broad spectrum of high-CV-risk patients

About Komboglyze

Komboglyze is a fixed-dose combination therapy containing saxagliptin (a DPP-4 inhibitor) and metformin in a single tablet


The efficacy of saxagliptin plus metformin as an add-on combination treatment for adult patients with Type 2 diabetes has been confirmed by the results of several key clinical studies

Safety and tolerability profiles

Evidence demonstrates that saxagliptin plus metformin is generally well tolerated, with a comparable adverse-event profile versus placebo